Conference Coverage
Videos
NewsNetwork
OncLive® TV
Peer Exchange
Insights
Attend An Event
State of the Science Summit
Regional Seminar Series
PER Conferences

OS by PS in Metastatic Pancreatic Cancer Treatment- Data From an Exploratory Subgroup Analysis

SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Neoadjuvant HER2+
More >>
<< View all publications

Special Issues

Targeting BCL-2 in Hematologic Malignancies
Targeting BCL-2 in Hematologic Malignancies
Focus on Pathways: Inhibition of the BCL-2 Pathway in Hematologic Malignancies   >   Articles
BCL-2: Mechanisms and Prevalence
BCL-2: Mechanisms and Prevalence
Focus on Pathways: Inhibition of the BCL-2 Pathway in Hematologic Malignancies   >   Articles
Erdafitinib Shows Promise in FGFR-Aberrant Cholangiocarcinoma
Erdafitinib Shows Promise in FGFR-Aberrant Cholangiocarcinoma
FGFR Inhibition in Cholangiocarcinoma: Update from the 2018 ESMO Congress   >   Articles
Pemigatinib Emerging as Potential Second-Line Treatment for Cholangiocarcinoma
Pemigatinib Emerging as Potential Second-Line Treatment for Cholangiocarcinoma
FGFR Inhibition in Cholangiocarcinoma: Update from the 2018 ESMO Congress   >   Articles
Cholangiocarcinoma Emerges as Key Target of FGFR Inhibitor Research
Cholangiocarcinoma Emerges as Key Target of FGFR Inhibitor Research
FGFR Inhibition in Cholangiocarcinoma: Update from the 2018 ESMO Congress   >   Articles
Infigratinib Active in Intrahepatic Cholangiocarcinoma
Infigratinib Active in Intrahepatic Cholangiocarcinoma
FGFR Inhibition in Cholangiocarcinoma: Update from the 2018 ESMO Congress   >   Articles
Efficacy and Safety of Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies
Efficacy and Safety of Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies
The Rationale for Bruton Tyrosine Kinase Inhibition in B-Cell Lymphomas   >   Articles
BTK Inhibitors: Real-World Insights on Patient Management and Therapy Selection
BTK Inhibitors: Real-World Insights on Patient Management and Therapy Selection
The Rationale for Bruton Tyrosine Kinase Inhibition in B-Cell Lymphomas   >   Articles
The Changing Treatment Landscape in MCL and CLL: A Review of Standards of Care
The Changing Treatment Landscape in MCL and CLL: A Review of Standards of Care
The Rationale for Bruton Tyrosine Kinase Inhibition in B-Cell Lymphomas   >   Articles
Expert Highlights Role of TMB in Evolving Immuno-Oncology Landscape
Expert Highlights Role of TMB in Evolving Immuno-Oncology Landscape
Focus on Pathways: Next-Generation Sequencing to Support Immuno-Oncology Therapy: The Emerging Role of Tumor Mutational Burden   >   Articles
Next Page >>
Publication Bottom Border
Border Publication
 
x